Literature DB >> 8115784

FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina.

C L Kosary1.   

Abstract

The prognostic impact of FIGO stage, histology, histologic grade, age and race in survival for cancers of the female gynecological (cervix, endometrium, ovary, vulva, vagina) were examined using cases obtained from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program that were diagnosed between 1973 and 1987. Utilizing Cox proportional hazards modeling and relative survival rates analysis of 17,119 cases of cervical cancer indicated that the International Federation of Gynecology and Obstetrics (FIGO) stage, histology, histological grade, lymph node status, and age at diagnosis were all independently prognostic. No evidence was found of survival differences between squamous cell carcinoma and adenocarcinoma. Younger women were not found to have a poorer prognosis, survival declined with increased age. Analysis of 41,120 cases of endometrial cancer indicated that FIGO stage, histology, histologic grade, lymph node status, age at diagnostic, and race were all prognostic factors. Clear cell adenocarcinoma, leiomyosarcoma, and mixed mullerian tumors were all found to have poorer prognosis. Analysis of 21,240 cases of ovarian cancer indicated that FIGO stage, histology, histologic grade, lymph node status, age at diagnosis, presence of ascites, and race were all prognostically significant. Analysis of 2,575 cases of vulvar cancer indicated that FIGO stage, histology, histologic grade, age, and race were all prognostically significant. Analysis of 916 cases of vaginal cancer indicated that FIGO stage, histologic grade, lymph node status, and age are all prognostically significant. Additional analysis of the data by combinations of independent prognostic factors indicates that the interaction of factors may be more predictive of outcome than any one factor separately.

Entities:  

Mesh:

Year:  1994        PMID: 8115784     DOI: 10.1002/ssu.2980100107

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  89 in total

1.  Endometrial endometrioid adenocarcinoma of the uterine corpus involving the cervix: some cases probably represent independent primaries.

Authors:  Liuyan Jiang; Anais Malpica; Michael T Deavers; Ming Guo; Luisa Lina Villa; Gerard Nuovo; Maria J Merino; Elvio G Silva
Journal:  Int J Gynecol Pathol       Date:  2010-03       Impact factor: 2.762

2.  Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials.

Authors:  Bradley J Monk; Chunqiao Tian; Peter G Rose; Rachelle Lanciano
Journal:  Gynecol Oncol       Date:  2007-02-02       Impact factor: 5.482

3.  Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.

Authors:  Federico Caobelli; Pierpaolo Alongi; Laura Evangelista; Maria Picchio; Giorgio Saladini; Marco Rensi; Onelio Geatti; Angelo Castello; Iashar Laghai; Cristina E Popescu; Carlotta Dolci; Cinzia Crivellaro; Silvia Seghezzi; Margarita Kirienko; Vincenzo De Biasi; Fabrizio Cocciolillo; Natale Quartuccio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-18       Impact factor: 9.236

4.  Lentiviral vector mediated-ASAP1 expression promotes epithelial to mesenchymal transition in ovarian cancer cells.

Authors:  Tao Zhang; Guannan Zhao; Chuanhe Yang; Peixin Dong; Hidemichi Watari; Lin Zeng; Lawrence M Pfeffer; Junming Yue
Journal:  Oncol Lett       Date:  2018-01-22       Impact factor: 2.967

5.  Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States.

Authors:  A M Stroup; L C Harlan; E L Trimble
Journal:  Gynecol Oncol       Date:  2007-12-21       Impact factor: 5.482

6.  Human cervical carcinoma xenograft models for studies of the physiological microenvironment of tumors.

Authors:  Christine Ellingsen; Ingrid Natvig; Jon-Vidar Gaustad; Kristine Gulliksrud; Tormod A M Egeland; Einar K Rofstad
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-13       Impact factor: 4.553

Review 7.  Magnetic resonance lymphography in gynaecological malignancies.

Authors:  Noor Jahan; Priya Narayanan; Andrea Rockall
Journal:  Cancer Imaging       Date:  2010-03-16       Impact factor: 3.909

8.  Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix.

Authors:  J-Y Park; D-Y Kim; J-H Kim; Y-M Kim; Y-T Kim; J-H Nam
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

9.  Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer.

Authors:  Digant Gupta; Carolyn A Lammersfeld; Pankaj G Vashi; Donald P Braun
Journal:  J Ovarian Res       Date:  2010-10-12       Impact factor: 4.234

10.  Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence.

Authors:  Renata A Tassi; Stefano Calza; Antonella Ravaggi; Eliana Bignotti; Franco E Odicino; Germana Tognon; Carla Donzelli; Marcella Falchetti; Elisa Rossi; Paola Todeschini; Chiara Romani; Elisabetta Bandiera; Laura Zanotti; Sergio Pecorelli; Alessandro D Santin
Journal:  BMC Cancer       Date:  2009-07-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.